Johnson & Johnson said on Monday human testing of its experimental vaccine for the coronavirus would begin by September and that it could be available for emergency use authorization in early 2021.
J&J also said it had committed more than $1 billion of investment along with U.S. agency Biomedical Advanced Research and Development Authority to co-fund vaccine research.
